Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant

Obesity Clinical Trial

Official title:

Investigation of the Effect of NNC0174-0833 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Females of Non-childbearing Potential

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04074174
• Other study ID #: NN9838-4517
• Secondary ID: U1111-1228-4219
• Status: Completed
• Phase: Phase 1
• Start date: September 12, 2019
• Est. completion date: March 6, 2020

Study information

• Verified date: January 2022
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study looks at how the study medicine affects the level in the blood of a birth control pill. The study also looks at how the study medicine affects the duration of emptying of the stomach. Participants will get 1 injection of study medicine once a week for 12 weeks by a study nurse at the clinic. The study medicine is injected with a thin needle in a skin fold in the stomach. In addition, participants will get 1 birth control pill per day for 8 days before the first dose of the study medicine and again after 10 weeks of dosing with the study medicine. Participants will also get a dose of acetaminophen before the first dose of the study medicine and again after 10 weeks of dosing with the study medicine. Acetaminophen is a mild painkiller but used here to assess the emptying of the stomach. The study will last for about 9 months, but participants will only be in the study for about 6 months. Participants will have 17 clinic visits with the study staff and some will be overnight visits. There will also be 3 phone calls with the study staff. At all visits, participants will have blood drawn along with other clinical assessments. Participants will be asked about their health, diseases and habits including mental health questionnaires. Participants must not be able to become pregnant if they want to participate in the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: March 6, 2020
• Est. primary completion date: March 6, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Female of non-childbearing potential, aged 18-65 years (both inclusive) at the time of signing informed consent.

• Body mass index (BMI) between 25.0 and 39.9 kg/m^2 (both inclusive). Overweight should be due to excess adipose tissue, as judged by the investigator.

Exclusion Criteria:

• Known or suspected hypersensitivity to trial products (including acetaminophen) or related products.

• Previous participation in this trial. Participation is defined as signed informed consent.

• Previous participation in trial(s) with NNC0174-0833 unless documented that the subject was assigned to placebo treatment. Participation is defined as randomised.

• Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.

Related Conditions & MeSH terms

• Obesity
• Overweight

Intervention

Drug:
• NNC0174-0833
NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks
• Oral contraceptive (OC) tablets
1 tablet daily on days 1-8 and days 79-86
• Acetaminophen
Single dose of acetaminophen as part of a standardised meal on day 1 and day 79

Locations

Country	Name	City	State
Canada	Novo Nordisk Investigational Site	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC0-24h,EE,SS area under the ethinylestradiol concentration-time curve during a dosing interval (0-24 hours) at steady state	h*pg/mL	Day 8 (predose to 24 hours post-dose) and Day 79 (predose to 24 hours post-dose)
Primary	AUC0-24h,LN,SS area under the levonorgestrel concentration-time curve during a dosing interval (0-24 hours) at steady state	h*pg/mL	Day 8 (predose to 24 hours post-dose) and Day 79 (predose to 24 hours post-dose)
Secondary	Cmax,EE, SS, maximum concentration of ethinylestradiol at steady state	pg/mL	Day 8 (predose to 24 hours post-dose) and Day 79 (predose to 24 hours post-dose)
Secondary	Cmax,LN,SS, maximum concentration of levonorgestrel at steady state	pg/mL	Day 8 (predose to 24 hours post-dose) and Day 79 (predose to 24 hours post-dose)
Secondary	tmax,EE,SS time to maximum concentration of ethinylestradiol at steady state	h	Day 8 (predose to 24 hours post-dose) and Day 79 (predose to 24 hours post-dose)
Secondary	tmax,LN,SS, time to maximum concentration of levonorgestrel at steady state	h	Day 8 (predose to 24 hours post-dose) and Day 79 (predose to 24 hours post-dose)
Secondary	AUC0-60min,para, area under the acetaminophen (paracetamol) concentration-time curve for 0-60 minutes following a standardised meal	h*microg/mL	Day 1 (predose to 60 minutes post-dose) and Day 79 (predose to 60 minutes post-dose)
Secondary	AUC0-360min,para, area under the acetaminophen (paracetamol) concentration-time curve for 0-360 minutes following a standardised meal	h*microg/mL	Day 1 (predose to 360 minutes post-dose) and Day 79 (predose to 360 minutes post-dose)